


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.


Listing of Claims:

1. (Currently Amended) A method of treating HIV infection, said method comprising administering a therapeutically effective amount of a [[A]] compound of formula (I):



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof, wherein

A and B each represents a radical of formula



ring E represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

ring F represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

R^1 represents hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl optionally substituted with formyl, C_{1-6} alkylcarbonyl,

C_{1-6} alkyloxycarbonyl, C_{1-6} alkylcarbonyloxy; or C_{1-6} alkyloxy C_{1-6} alkylcarbonyl substituted with C_{1-6} alkyloxycarbonyl;

R^2 represents cyano; aminocarbonyl; mono- or di(C_{1-4} alkyl)aminocarbonyl; C_{1-6} alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; C_{2-6} alkenyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; or C_{2-6} alkynyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl;

X_1 represents $-NR^5$ -, $-NH-NH$ -, $-N=N$ -, $-O$ -, $-C(=O)$ -, $-C_{1-4}$ alkanediyl-, $-CHOH$ -, $-S$ -, $-S(=O)_p$ -, $-X_2-C_{1-4}$ alkanediyl-, $-C_{1-4}$ alkanediyl- X_2 -, or $-C_{1-4}$ alkanediyl- X_2-C_{1-4} alkanediyl-;

X_2 represents $-NR^5$ -, $-NH-NH$ -, $-N=N$ -, $-O$ -, $-C(=O)$ -, $-CHOH$ -, $-S$ -, or $-S(=O)_p$ -,

m represents an integer of value 1, 2, 3 or 4;

R^3 represents cyano; aminocarbonyl; amino; halo; NHR^{13} ; $NR^{13}R^{14}$; $-C(=O)-NHR^{13}$; $-C(=O)-NR^{13}R^{14}$; $-C(=O)-R^{15}$; $-CH=N-NH-C(=O)-R^{16}$; C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from R^{3a} ;

C_{1-6} alkyloxy optionally substituted with one or more substituents each independently

selected from R^{3a} ; C_{1-6} alkyloxy C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from R^{3a} ; C_{2-6} alkenyl optionally substituted with one or more substituents each independently selected from R^{3a} ; C_{2-6} alkynyl optionally substituted with one or more substituents each independently selected from R^{3a} ;
 $-C(=N-O-R^8)-C_{1-4}$ alkyl; R^7 or $-X_3-R^7$;
 R^{3a} represents halo, cyano, hydroxy, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl, $-C(=O)-O-C_{1-6}$ alkyl, $-C(=O)-polyhaloC_{1-6}$ alkyl, $-C(=O)-O-polyhaloC_{1-6}$ alkyl or R^7 ;
 X_3 represents $-NR^5$ -, $-NH-NH$ -, $-N=N$ -, $-O$ -, $-C(=O)$ -, $-S$ -, $-S(=O)_p$ -,
 $-X_{4a}-C_{1-4}$ alkanediyl-, $-C_{1-4}$ alkanediyl- X_{4b} -, $-C_{1-4}$ alkanediyl- $X_{4a}-C_{1-4}$ alkanediyl-, or
 $-C(=N-OR^8)-C_{1-4}$ alkanediyl-;
 X_{4a} represents $-NR^5$ -, $-NH-NH$ -, $-N=N$ -, $-C(=O)$ -, $-S$ -, or $-S(=O)_p$ -,
 X_{4b} represents $-NH-NH$ -, $-N=N$ -, $-O$ -, $-C(=O)$ -, $-S$ -, or $-S(=O)_p$ -,
each R^4 independently represents hydroxy; halo; C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from R^{4a} ; C_{2-6} alkenyl optionally substituted with one or more substituents each independently selected from R^{4a} ;
 C_{2-6} alkynyl optionally substituted with one or more substituents each independently selected from R^{4a} ; C_{3-7} cycloalkyl; C_{1-6} alkyloxy; C_{1-6} alkyloxycarbonyl;
 C_{1-6} alkylcarbonyloxy; carboxyl; formyl; cyano; nitro; amino; mono- or
di(C_{1-6} alkyl)amino; polyhalo C_{1-6} alkyl; polyhalo C_{1-6} alkyloxy; polyhalo C_{1-6} alkylthio;
 $-S(=O)_pR^6$; $-NH-S(=O)_pR^6$; $-C(=O)R^6$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $NHC(=O)R^6$;
 $C(=NH)R^6$; or R^7 ;
 R^{4a} represents halo, cyano, NR^9R^{10} , hydroxy or $-C(=O)R^6$;
 R^5 represents hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl optionally substituted with formyl, C_{1-6} alkylcarbonyl,
 C_{1-6} alkyloxycarbonyl or C_{1-6} alkylcarbonyloxy; or C_{1-6} alkyloxy C_{1-6} alkylcarbonyl substituted with C_{1-6} alkyloxycarbonyl;
 R^6 represents C_{1-6} alkyl, amino, mono- or di(C_{1-4} alkyl)amino or polyhalo C_{1-4} alkyl;
 R^7 represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may, whenever possible, optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono or di(C_{1-6} alkyl)amino C_{1-6} alkyl, formyl, C_{1-6} alkylcarbonyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl, C_{1-6} alkylthio, cyano, nitro, polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy, aminocarbonyl, $-CH(=N-O-R^8)$, R^{7a} , $-X_3-R^{7a}$ or $R^{7a}-C_{1-4}$ alkanediyl-;


R^{7a} represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto,

C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸);

R⁸ represents hydrogen, C₁₋₄alkyl optionally substituted with aryl, or aryl;

R⁹ and R¹⁰ each independently represent hydrogen; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhaloC₁₋₄alkyl, polyhaloC₁₋₄alkyloxy, polyhaloC₁₋₄alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, or R⁷; or

R⁹ and R¹⁰ may be taken together to form a bivalent ~~or trivalent~~ radical of formula



R¹¹ represents cyano; C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino or aminocarbonyl; C₁₋₄alkylcarbonyl;


C₁₋₄alkyloxycarbonyl; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹² represents hydrogen or C₁₋₄alkyl;

R¹³ and R¹⁴ each independently represent C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

C₂₋₆alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;
R¹⁵ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;
R¹⁶ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or R⁷;
-C-D- represents a bivalent radical of formula
-N=CH-NR¹⁷- (c-1); or
-NR¹⁷-CH=N- (c-2);
R¹⁷ represents hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, mono-or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkyloxycarbonyl or aryl;
p represents an integer of value 1 or 2;
aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷;
provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).


2. (Original) A compound as defined in claim 1 provided that when R² represents aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl then R³ represents cyano; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; C₁₋₆alkyl substituted with one or more substituents each independently selected from R^{3b}; C₁₋₆alkyloxy substituted with one or more substituents each independently selected from R^{3a}; C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from R^{3a}; C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from R^{3a}; C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from R^{3a}; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷; with R^{3b} representing cyano, hydroxy, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl, -C(=O)-polyhaloC₁₋₆alkyl, -C(=O)-O-polyhaloC₁₋₆alkyl or R⁷.
3. (Currently Amended) A compound according to claim 2 wherein the compound has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C, D and m are as defined in claim 1.


4. (Currently Amended) A compound according to claim 3 wherein the compound of formula (I-A) has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C and D are as defined in claim 1.


5. (Currently Amended) A compound according to claim 2 wherein the compound has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C, D and m are as defined in claim 1.


6. (Currently Amended) A compound according to claim 5 wherein the compound of formula (I-B) has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C and D are as defined in claim 1.

7. (Previously Presented) A compound according to claim 2 wherein ring E is phenyl.
8. (Previously Presented) A compound according to claim 2 wherein ring F is phenyl.
9. (Currently Amended) A compound according to claim 2 wherein the compound has the formula



a *N*-oxide, a pharmaceutically acceptable addition salt, ~~a quaternary amine~~ or a stereochemically isomeric form thereof, wherein

$-a^1=a^2-C(R^2)=a^3-a^4-$ represents a bivalent radical of formula

$-CH=CH-C(R^2)=CH-CH=$ (a-1);

$-N=CH-C(R^2)=CH-CH=$ (a-2);

$-CH=N-C(R^2)=CH-CH=$ (a-3);

$-N=CH-C(R^2)=N-CH=$ (a-4);

$-N=CH-C(R^2)=CH-N=$ (a-5);

$-CH=N-C(R^2)=N-CH=$ (a-6); or

$-N=N-C(R^2)=CH-CH=$ (a-7);

$-b^1=b^2-b^3=b^4-$ represents a bivalent radical of formula

$-CH=CH-CH=CH-$ (b-1);

$-N=CH-CH=CH-$ (b-2);

-N=CH-N=CH- (b-3);
 -N=CH-CH=N- (b-4); or
 -N=N-CH=CH- (b-5);

-C-D- represents a bivalent radical of formula

-N=CH-NR¹⁷- (c-1); or
 -NR¹⁷-CH=N- (c-2);

m represents an integer of value 1, 2, 3 and in case -b¹=b²-b³=b⁴- is (b-1), then m may also be 4;

R¹ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;

R² represents cyano; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl; C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or C₂₋₆alkynyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

X₁ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, C₁₋₄alkanediyl, -CHOH-, -S-, -S(=O)_p-, -X₂-C₁₋₄alkanediyl- or -C₁₋₄alkanediyl-X₂-;


X₂ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)_p-;

R³ represents NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³; -C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; cyano; halo; C₁₋₆alkyl; polyhaloC₁₋₆alkyl; C₁₋₆alkyl substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyl substituted with hydroxy and a second substituent selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxy optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; -C(=N-O-R⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷;

X₃ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-, -X_{4b}-C₁₋₄alkanediyl-, -C₁₋₄alkanediyl-X_{4a}-, -C₁₋₄alkanediyl-X_{4b}-C₁₋₄alkanediyl-, -C(=N-OR⁸)-C₁₋₄alkanediyl-; with X_{4a} being -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-; and with X_{4b} being -NH-NH-, -N=N-, -C(=O)-, -S-, -S(=O)_p-;

- each R⁴ independently represents halo, hydroxy, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyl, formyl, amino, mono- or di(C₁₋₄alkyl)amino or R⁷;
- R⁵ is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl or C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;
- R⁶ is C₁₋₄alkyl, amino, mono- or di(C₁₋₄alkyl)amino or polyhaloC₁₋₄alkyl;
- R⁷ is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸), R^{7a}, -X₃-R^{7a} or R^{7a}-C₁₋₄alkanediyl-;
- R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, or -CH(=N-O-R⁸);
- R⁸ is hydrogen, C₁₋₄alkyl optionally substituted with aryl, or aryl;
- R⁹ and R¹⁰ each independently are hydrogen; C₁₋₆alkyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxycarbonyl, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhaloC₁₋₄alkyl, polyhaloC₁₋₄alkyloxy, polyhaloC₁₋₄alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

R^9 and R^{10} may be taken together to form a bivalent ~~or trivalent~~ radical of formula



R^{11} represents cyano; C_{1-4} alkyl optionally substituted with C_{1-4} alkyloxy, cyano, amino, mono- or di(C_{1-4} alkyl)amino or aminocarbonyl; C_{1-4} alkylcarbonyl;

C_{1-4} alkyloxycarbonyl; aminocarbonyl; mono- or di(C_{1-4} alkyl)aminocarbonyl;

R^{12} represents hydrogen or C_{1-4} alkyl;

R^{13} and R^{14} each independently represent C_{1-6} alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; C_{2-6} alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl;

C_{2-6} alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl;

R^{15} represents C_{1-6} alkyl substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl;

R^{16} represents C_{1-6} alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C_{1-4} alkyl)aminocarbonyl; or R^7 ;

R^{17} represents hydrogen; C_{1-6} alkyl; or C_{1-6} alkyl substituted with aryl;

p is 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, mono or di(C_{1-6} alkyl)amino C_{1-6} alkyl,

C_{1-6} alkylcarbonyl, C_{3-7} cycloalkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxycarbonyl,

C_{1-6} alkylthio, cyano, nitro, polyhalo C_{1-6} alkyl, polyhalo C_{1-6} alkyloxy, aminocarbonyl, R^7 or $-X_3-R^7$;

provided that when R^2 represents aminocarbonyl or mono- or

di(C_{1-4} alkyl)aminocarbonyl then R^3 represents $-C(=O)-R^{15}$; $-CH=N-NH-C(=O)-R^{16}$; cyano;

C_{1-6} alkyl substituted with one or more substituents each independently selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{1-6} alkyl substituted with hydroxy and a second substituent selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{1-6} alkyloxy C_{1-6} alkyl optionally substituted with one or more substituents each independently

selected from cyano, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl or R^7 ; C_{1-6} alkyloxy

substituted with one or more substituents each independently selected from cyano, NR^9R^{10} ,

$-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $\text{C}_{2-6}\text{alkenyl}$ optionally substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ;

$\text{C}_{2-6}\text{alkynyl}$ optionally substituted with one or more substituents each independently selected from halo, cyano, NR^9R^{10} , $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$, $-\text{C}(=\text{O})-\text{C}_{1-6}\text{alkyl}$ or R^7 ; $-\text{C}(=\text{N}-\text{O}-\text{R}^8)-\text{C}_{1-4}\text{alkyl}$; R^7 or $-\text{X}_3-\text{R}^7$.

10. (Previously Presented) A compound according to claim 2 wherein R^2 represents cyano; aminocarbonyl; mono- or di($\text{C}_{1-4}\text{alkyl}$)aminocarbonyl; $\text{C}_{1-6}\text{alkyl}$ substituted with cyano, aminocarbonyl or mono- or di($\text{C}_{1-4}\text{alkyl}$)aminocarbonyl; $\text{C}_{2-6}\text{alkenyl}$ substituted with cyano, aminocarbonyl or mono- or di($\text{C}_{1-4}\text{alkyl}$)aminocarbonyl; or $\text{C}_{2-6}\text{alkynyl}$ substituted with cyano, aminocarbonyl or mono- or di($\text{C}_{1-4}\text{alkyl}$)aminocarbonyl.
11. (Previously Presented) A compound according to claim 2 wherein R^2 represents cyano or aminocarbonyl.
12. (Previously Presented) A compound according to claim 2 wherein R^3 is cyano; aminocarbonyl; $\text{C}_{1-6}\text{alkyl}$ optionally substituted with cyano or aminocarbonyl; $\text{C}_{1-6}\text{alkyloxy}$ optionally substituted with cyano or aminocarbonyl; $\text{C}_{2-6}\text{alkenyl}$ substituted with cyano or aminocarbonyl.
13. (Previously Presented) A compound according to claim 2 wherein m is 2; R^1 represents hydrogen; R^2 represents cyano, aminocarbonyl or $\text{C}_{1-6}\text{alkyl}$; R^3 represents cyano; $\text{C}_{1-6}\text{alkyl}$; $\text{C}_{1-6}\text{alkyl}$ substituted with cyano; $\text{C}_{1-6}\text{alkyloxy}$ optionally substituted with cyano; $\text{C}_{2-6}\text{alkenyl}$ substituted with cyano or $-\text{C}(=\text{O})-\text{NR}^9\text{R}^{10}$; each R^4 independently represents halo, $\text{C}_{1-6}\text{alkyl}$ or $\text{C}_{1-6}\text{alkyloxy}$; X_1 represents $-\text{NR}^5-$ or $-\text{O}-$; R^5 represents hydrogen; R^9 and R^{10} each independently are hydrogen or $\text{C}_{1-6}\text{alkyl}$; or R^9 and R^{10} may be taken together to form a bivalent radical of formula $-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2-\text{CH}_2-$ (d-3); R^{17} is hydrogen; $\text{C}_{1-6}\text{alkyl}$ optionally substituted with hydroxy, cyano, aminocarbonyl, $\text{C}_{1-4}\text{alkyloxycarbonyl}$ or aryl; aryl is phenyl substituted with $\text{C}_{1-6}\text{alkyloxy}$.

14. (Cancelled).


15. (Cancelled).

16. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound ~~as claimed in~~ of claim 1.

17. (Currently Amended) A process for preparing a pharmaceutical composition according to claim 16 comprising a therapeutically effective amount of a compound ~~as claimed in~~ of claim 1 intimately mixed with a pharmaceutically acceptable carrier.


18. (Currently Amended) A process for preparing a compound as claimed in claim 2, comprising:

a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III) in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,




with W₁ representing a suitable leaving group, R^{17b} representing C₁₋₆alkyl optionally substituted with aryl, and A and B being defined as in claim 2 and wherein X₁ represents -NR⁵-, -O- or -S-;

b) reacting an intermediate of formula (II'-a) or (II'-b) with an intermediate of formula (III') in the presence of a suitable catalyst, a suitable ligand, a suitable base, and a suitable solvent,




with W_1 representing a suitable leaving group, R^{17b} representing C_{1-6} alkyl optionally substituted with aryl, and A and B being defined as in claim 2 and wherein X_1 represents $-NR^5$ -, $-O$ - or $-S$ -;

c) by converting a compound of formula (I-a) or (I-b) into a compound of formula (I-c) and (I-d) by reaction with a suitable acid,




with R^{17b} representing C_{1-6} alkyl ~~optionally~~ substituted with aryl, and A and B being defined as in claim 2;

d) converting a compound of formula (I-c) into a compound of formula (I-e) by reaction with an intermediate of formula $R^{17c}-W_2$ in the presence of a suitable base and a suitable solvent,





with W_2 representing a suitable leaving group, R^{17c} representing C_{1-6} alkyl optionally substituted with cyano or C_{1-4} alkyloxycarbonyl, and A and B being defined as in claim 2;

e) converting a compound of formula (I-e-1) into a compound of formula (I-f), by reaction with NH_3 in the presence of a suitable solvent,




with A and B being defined as in claim 2;

f) converting a compound of formula (I-e-1) into a compound of formula (I-g), by reaction with NaBH_4 in the presence of a suitable solvent,



with A and B being defined as in claim 2;

g) converting a compound of formula (I-f) into a compound of formula (I-h), by reaction with POCl_3 in the presence of a suitable solvent,











with A and B being defined as in claim 2;











~~or, if desired, further converting compounds of formula (I) into each other following art known transformations;~~ or further, if desired, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or conversely, converting the acid addition salt form into the free base by treatment with alkali; or, if desired, preparing stereochemically isomeric forms, *N*-oxide forms or quaternary amines thereof.


19. (Previously Presented) A product containing (a) a compound as defined in claim 1 , and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.
20. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 1 , and (b) another antiretroviral compound.
21. (Currently Amended) A product containing (a) a compound as defined in claim ~~14~~ 25, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.
22. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim ~~14~~ 25 and (b) another antiretroviral compound.
23. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim ~~14~~ 25.

24. (Currently Amended) A process for preparing a pharmaceutical composition according to claim 23 comprising a therapeutically effective amount of a compound as claimed in claim 14 25 intimately mixed with a pharmaceutically acceptable carrier.

25. (New) A compound selected from the group consisting of:







and *N*-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereochemically isomeric forms thereof.